Clinical Trials in Dallas

Showing 11701-11720 of 17,468 trials

Sorafenib and High-Dose Carboplatin, Paclitaxel, and External-Beam Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer

NCT00547443

RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving sorafenib together with high-dose chemotherapy and external-beam radiation therapy may kill more tumor cells. PURPOSE: This randomized phase I/II trial is studying the side effects and best dose of sorafenib when given together with high-dose carboplatin, paclitaxel, and external-beam radiation therapy in treating patients with stage III non-small cell lung cancer.

Lung Cancer

University of Texas Southwestern Medical CenterStarted Jul 2007

Arlington, Texas, United States • Dallas, Texas, United States

TERMINATEDPhase 1< 1 mile

A Safety Study in Participants With Advanced Solid Tumors

NCT01284335

The purpose of this study is to determine a safe dose of LY573636 (tasisulam) when used in 5 separate combinations with an approved cancer medication for treating participants with advanced cancer. Data from this study will be reviewed for any side effects or anti-tumor activity that may be associated with the LY573636 combination treatments.

Advanced Solid Tumors

Eli Lilly and Company234 participantsStarted Jul 2008

Birmingham, Alabama, United States • Fayetteville, Arkansas, United States • Denver, Colorado, United States +16 more locations

Sorafenib and High-Dose Carboplatin, Paclitaxel, and External-Beam Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer

A Safety Study in Participants With Advanced Solid Tumors

Find Trials by Condition in Dallas

A Study to Evaluate Efficacy and Safety of QPI-1002 for Prevention of Acute Kidney Injury Following Cardiac Surgery

Physical Therapy Program for Prevention of Shoulder Pain After Device Implant

The Effect of Atrial Fibrillation Hemodynamics on Regulation of Cerebral Blood Flow

Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer

A Dose Escalation Study of a Combination Antihypertensive Drug in the Treatment of Various Groups of Patients Who do Not Respond to Single Drug Treatment of Their High Blood Pressure

Oral Hepatitis C Treatment for Indolent Lymphoma (OPTImaL) Study

A Study to Assess the Efficacy and Safety of AXS-02 in Subjects With Knee OA Associated With Bone Marrow Lesions

Expanded Access Use of Omegaven® in the Treatment of Parenteral Nutrition Induced Liver Injury in Children

Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRO

Topotecan in Treating Women With Persistent or Recurrent Cervical Cancer

Pharmacodynamic Evaluation of Switching From Ticagrelor to Prasugrel in Subjects With Stable Coronary Artery Disease

Study of LY573636-sodium in Essential Thrombocythemia and Acute Myeloid Leukemia

Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors

A Study of Vadastuximab Talirine Given Prior to or After Allogeneic Hematopoietic Stem Cell Transplant in AML Patients

Dacomitinib (PF-00299804) As A Single Oral Agent In Selected Patients With Adenocarcinoma Of The Lung

Axitinib For The Treatment Of Advanced Hepatocellular Carcinoma

Aspen Spinous Process Fixation System for Use in PLF in Patients With Spondylolisthesis

Detection and Neurological Impact of CerebroVascular Events In Noncardiac Surgery PatIents: A COhort EvaluatioN